Related references
Note: Only part of the references are listed.Improved survival in patients with thyroid function test abnormalities secondary to immune-checkpoint inhibitors
Joana Lima Ferreira et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2021)
Baseline serum TSH levels predict the absence of thyroid dysfunction in cancer patients treated with immunotherapy
L. Brilli et al.
JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION (2021)
Thyroid Immune-Related Adverse Events in Patients with Cancer Treated with anti-PD1/anti-CTLA4 Immune Checkpoint Inhibitor Combination: Clinical Course and Outcomes
David Tak Wai Lui et al.
ENDOCRINE PRACTICE (2021)
Thyroid function abnormality induced by PD-1 inhibitors have a positive impact on survival in patients with non-small cell lung cancer
Yuwen Zhou et al.
INTERNATIONAL IMMUNOPHARMACOLOGY (2021)
Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma
Robert Motzer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Distinct Cytokine Signatures in Thyroiditis Induced by PD-1 or CTLA-4 Blockade: Insights from a New Mouse Model
Silvia Ippolito et al.
THYROID (2021)
Higher baseline TSH levels predict early hypothyroidism during cancer immunotherapy
C. Luongo et al.
JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION (2021)
Endocrine toxicity of cancer immunotherapy: clinical challenges
Bliss Anderson et al.
ENDOCRINE CONNECTIONS (2021)
Immune checkpoint inhibitor related hypophysitis: diagnostic criteria and recovery patterns
Ha Nguyen et al.
ENDOCRINE-RELATED CANCER (2021)
Thyroid Immune-related Adverse Events Following Immune Checkpoint Inhibitor Treatment
Christopher A. Muir et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2021)
Endocrine toxicities of immune checkpoint inhibitors
Jordan J. Wright et al.
NATURE REVIEWS ENDOCRINOLOGY (2021)
CD4+ T cells are essential for the development of destructive thyroiditis induced by anti-PD-1 antibody in thyroglobulin-immunized mice
Yoshinori Yasuda et al.
SCIENCE TRANSLATIONAL MEDICINE (2021)
Factors Modifying Outcome After MIBG Therapy in Children With Neuroblastoma-A National Retrospective Study
Marek Ussowicz et al.
FRONTIERS IN ONCOLOGY (2021)
Survival benefit of endocrine dysfunction following immune checkpoint inhibitors for nonthyroidal cancers
Anupam Kotwal et al.
CURRENT OPINION IN ENDOCRINOLOGY DIABETES AND OBESITY (2021)
Hypophysitis from immune checkpoint inhibitors: challenges in diagnosis and management
Anupam Kotwal
CURRENT OPINION IN ENDOCRINOLOGY DIABETES AND OBESITY (2021)
Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1/2 study
Vivek Subbiah et al.
LANCET DIABETES & ENDOCRINOLOGY (2021)
Adrenal Insufficiency From Immune Checkpoint Inhibitors Masquerading as Sepsis
Dua'A Abdallah et al.
JCO ONCOLOGY PRACTICE (2021)
Thyroid Immune-related Adverse Events Following Immune Checkpoint Inhibitor Treatment
Christopher A. Muir et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2021)
THYROID DYSFUNCTION, RECOVERY, AND PROGNOSIS IN MELANOMA PATIENTS TREATED WITH IMMUNE CHECKPOINT INHIBITORS: A RETROSPECTIVE REVIEW
Mazen Al Mushref et al.
ENDOCRINE PRACTICE (2020)
Immune checkpoint inhibitor diabetes mellitus: a novel form of autoimmune diabetes
Z. Quandt et al.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2020)
Thyroid disorders in programmed death 1 inhibitor-treated patients: Is previous therapy with tyrosine kinase inhibitors a predisposing factor?
Emilia Sbardella et al.
CLINICAL ENDOCRINOLOGY (2020)
On-target Toxicities Predictive of Survival in Metastatic Renal Cell Carcinoma (mRCC) Treated With Sunitinib: A Multicenter Retrospective Study
Elena Bolzacchini et al.
CLINICAL GENITOURINARY CANCER (2020)
Management of Immunotherapy-Related Toxicities, Version 1.2020 Featured Updates to the NCCN Guidelines
John A. Thompson et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2020)
PD-L1 Inhibitor-Induced Thyroiditis Is Associated with Better Overall Survival in Cancer Patients
Anupam Kotwal et al.
THYROID (2020)
Lenvatinib Plus Pembrolizumab in Patients With Advanced Endometrial Cancer
Vicky Makker et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Overt Thyroid Dysfunction and Anti-Thyroid Antibodies Predict Response to Anti-PD-1 Immunotherapy in Cancer Patients
Edwin A. Basak et al.
THYROID (2020)
Thyroid Toxicity Following Immune Checkpoint Inhibitor Treatment in Advanced Cancer
Christopher A. Muir et al.
THYROID (2020)
Immune Checkpoint Inhibitor-Induced Thyroiditis Is Associated with Increased Intrathyroidal T Lymphocyte Subpopulations
Anupam Kotwal et al.
THYROID (2020)
Lenvatinib prolongs the progression-free survival time of patients with intermediate-stage hepatocellular carcinoma refractory to transarterial chemoembolization: A multicenter cohort study using data mining analysis
Shigeo Shimose et al.
ONCOLOGY LETTERS (2020)
Efficacy of Selpercatinib in RET-Altered Thyroid Cancers
L. J. Wirth et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Impact of Adverse Events on the Progression-Free Survival of Patients with Advanced Hepatocellular Carcinoma Treated with Lenvatinib: A Multicenter Retrospective Study
Takamasa Ohki et al.
DRUGS-REAL WORLD OUTCOMES (2020)
Thyroid dysfunction due to 131I-metaiodobenzylguanidine in patients with neuroblastoma
Eulalia Garrido Magana et al.
REVISTA CHILENA DE PEDIATRIA-CHILE (2020)
Endocrine Toxicity of Cancer Immunotherapy Targeting Immune Checkpoints
Lee-Shing Chang et al.
ENDOCRINE REVIEWS (2019)
Immune Checkpoint Inhibitor-Induced Hypoparathyroidism Associated With Calcium-Sensing Receptor-Activating Autoantibodies
Paramarajan Piranavan et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2019)
A Systematic Review and Meta-Analysis of Endocrine-Related Adverse Events Associated with Immune Checkpoint Inhibitors
Jeroen de Filette et al.
HORMONE AND METABOLIC RESEARCH (2019)
mpact of sunitinib-induced hypothyroidism on survival of patients with metastatic renal cancer
Theofanis Vasileiadis et al.
BMC CANCER (2019)
Pembrolizumab-Induced Thyroiditis
Brittney A. Imblum et al.
ENDOCRINE PATHOLOGY (2019)
BASELINE TSH LEVEL IS ASSOCIATED WITH RISK OF ANTI-PD-1-INDUCED THYROID DYSFUNCTION
Rena M. Pollack et al.
ENDOCRINE PRACTICE (2019)
Incidence, features, and prognosis of immune-related adverse events involving the thyroid gland induced by nivolumab
Ichiro Yamauchi et al.
PLOS ONE (2019)
Axitinib-Induced Hypothyroidism as a Predictor of Long-Term Survival in Patients with Metastatic Renal Cell Carcinoma
Shinya Takada et al.
UROLOGIA INTERNATIONALIS (2019)
Efficacy and Safety of High-Specific-Activity 131I-MIBG Therapy in Patients with Advanced Pheochromocytoma or Paraganglioma
Daniel A. Pryma et al.
JOURNAL OF NUCLEAR MEDICINE (2019)
The correlation between the incidence of adverse events and progression-free survival in patients treated with cabozantinib for metastatic renal cell carcinoma (mRCC)
Jakub Kucharz et al.
MEDICAL ONCOLOGY (2019)
Thyroid dysfunction induced by nivolumab: searching for disease patterns and outcomes
Inmaculada Peiro et al.
ENDOCRINE (2019)
Immune checkpoint inhibitors: an emerging cause of insulin-dependent diabetes
Anupam Kotwal et al.
BMJ OPEN DIABETES RESEARCH & CARE (2019)
Lenvatinib-induced thyroid abnormalities in unresectable hepatocellular carcinoma
Yohei Koizumi et al.
ENDOCRINE JOURNAL (2019)
The spectrum, incidence, kinetics and management of endocrinopathies with immune checkpoint inhibitors for metastatic melanoma
Emma S. Scott et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2018)
Development of thyroid dysfunction is associated with clinical response to PD-1 blockade treatment in patients with advanced non-small cell lung cancer
Hye In Kim et al.
ONCOIMMUNOLOGY (2018)
A novel thyroid function index associated with opposite therapeutic outcomes in advanced hepatocellular carcinoma patients receiving chemotherapy or sorafenib
Yu-De Chu et al.
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY (2018)
Collateral Damage: Insulin-Dependent Diabetes Induced With Checkpoint Inhibitors
Angeliki Stamatouli et al.
DIABETES (2018)
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
Julie R. Brahmer et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial
Masatoshi Kudo et al.
LANCET (2018)
Axitinib in combination with pembrolizumab in patients with advanced renal cell cancer: a non-randomised, open-label, dose-finding, and dose-expansion phase 1b trial
Michael B. Atkins et al.
LANCET ONCOLOGY (2018)
Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma
G. K. Abou-Alfa et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Risk Factors for New Hypothyroidism During Tyrosine Kinase Inhibitor Therapy in Advanced Nonthyroidal Cancer Patients
Melissa G. Lechner et al.
THYROID (2018)
Association of Immune-Related Adverse Events With Nivolumab Efficacy in Non-Small Cell Lung Cancer
Koji Haratani et al.
JAMA ONCOLOGY (2018)
Incidence of Endocrine Dysfunction Following the Use of Different Immune Checkpoint Inhibitor Regimens A Systematic Review and Meta-analysis
Romualdo Barroso-Sousa et al.
JAMA ONCOLOGY (2018)
MIBG (metaiodobenzylguanidine) theranostics in pediatric and adult malignancies
Archi Agrawal et al.
BRITISH JOURNAL OF RADIOLOGY (2018)
Immune-Related Thyroiditis with Immune Checkpoint Inhibitors
Priyanka C. Iyer et al.
THYROID (2018)
Unique cytologic features of thyroiditis caused by immune checkpoint inhibitor therapy for malignant melanoma
Trevor E. Angell et al.
GENES & DISEASES (2018)
Patients With Antithyroid Antibodies Are Prone To Develop Destructive Thyroiditis by Nivolumab: A Prospective Study
Tomoko Kobayashi et al.
JOURNAL OF THE ENDOCRINE SOCIETY (2018)
Antibody-mediated thyroid dysfunction during T-cell checkpoint blockade in patients with non-small-cell lung cancer
J. C. Osorio et al.
ANNALS OF ONCOLOGY (2017)
Sorafenib-Induced Changes in Thyroid Hormone Levels in Patients Treated for Hepatocellular Carcinoma
Carolien M. Beukhof et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2017)
Pembrolizumab-Induced Thyroiditis: Comprehensive Clinical Review and Insights Into Underlying Involved Mechanisms
Danae A. Delivanis et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2017)
Norepinephrine Transporter as a Target for Imaging and Therapy
Neeta Pandit-Taskar et al.
JOURNAL OF NUCLEAR MEDICINE (2017)
Clinical Features of Nivolumab-Induced Thyroiditis: A Case Series Study
Ichiro Yamauchi et al.
THYROID (2017)
Characterization of Thyroid Disorders in Patients Receiving Immune Checkpoint Inhibition Therapy
Hyunju Lee et al.
CANCER IMMUNOLOGY RESEARCH (2017)
Nivolumab induced myxedema crisis
Uqba Khan et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2017)
Tremelimumab-Induced Graves Hyperthyroidism
Earn H. Gan et al.
EUROPEAN THYROID JOURNAL (2017)
Thyroid abnormalities following the use of cytotoxic T-lymphocyte antigen-4 and programmed death receptor protein-1 inhibitors in the treatment of melanoma
D. L. Morganstein et al.
CLINICAL ENDOCRINOLOGY (2017)
Prognostic role of the cumulative toxicity in patients affected by metastatic renal cells carcinoma and treated with first-line tyrosine kinase inhibitors
Roberto Iacovelli et al.
ANTI-CANCER DRUGS (2017)
Immunotherapy and hypophysitis: clinical presentation, treatment, and biologic insights
Alexander Faje
PITUITARY (2016)
Assessing Immune-Related Adverse Events of Efficacious Combination Immunotherapies in Preclinical Models of Cancer
Jing Liu et al.
CANCER RESEARCH (2016)
Hypothyroidism Side Effect in Patients Treated with Sunitinib or Sorafenib: Clinical and Structural Analyses
Mao Shu et al.
PLOS ONE (2016)
Hypothyroidism and Thyroid Autoimmunity as a Prognostic Biomarker of Better Response in Metastatic Cancer Long-Term Survivors Treated with Sunitinib
Fabiana Pani et al.
THYROID (2016)
Draft guidelines regarding appropriate use of 131I-MIBG radiotherapy for neuroendocrine tumors
Seigo Kinuya et al.
ANNALS OF NUCLEAR MEDICINE (2015)
Autoimmune thyroid disorders
Alessandro Antonelli et al.
AUTOIMMUNITY REVIEWS (2015)
Correlation of Degree of Hypothyroidism With Survival Outcomes in Patients With Metastatic Renal Cell Carcinoma Receiving Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitors
Erin B. Bailey et al.
CLINICAL GENITOURINARY CANCER (2015)
Real-world use of sunitinib in Japanese patients with advanced renal cell carcinoma: efficacy, safety and biomarker analyses in 1689 consecutive patients
Hideyuki Akaza et al.
JAPANESE JOURNAL OF CLINICAL ONCOLOGY (2015)
Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma
T. K. Choueiri et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Thyroid Dysfunction in Patients with Metastatic Carcinoma Treated with Sunitinib: Is Thyroid Autoimmunity Involved?
Fabiana Pani et al.
THYROID (2015)
Revised American Thyroid Association Guidelines for the Management of Medullary Thyroid Carcinoma
Samuel A. Wells et al.
THYROID (2015)
Long-term efficacy of current thyroid prophylaxis and future perspectives on thyroid protection during 131I-metaiodobenzylguanidine treatment in children with neuroblastoma
S. C. Clement et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2015)
Nothing but NET: A Review of Norepinephrine Transporter Expression and Efficacy of I-131-mIBG Therapy
Keri A. Streby et al.
PEDIATRIC BLOOD & CANCER (2015)
Endocrine-related adverse events following ipilimumab in patients with advanced melanoma: a comprehensive retrospective review from a single institution
Mabel Ryder et al.
ENDOCRINE-RELATED CANCER (2014)
Risk of thyroid dysfunction in patients with solid tumors treated with VEGF receptor tyrosine kinase inhibitors: a critical literature review and meta analysis
Omar Abdel-Rahman et al.
EXPERT REVIEW OF ANTICANCER THERAPY (2014)
Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial
Marcia S. Brose et al.
LANCET (2014)
Thyroid Hormone Inactivation in Gastrointestinal Stromal Tumors
Michelle A. Maynard et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Anti-PD1 Following Ipilimumab for Mucosal Melanoma: Durable Tumor Response Associated with Severe Hypothyroidism and Rhabdomyolysis
Le Min et al.
CANCER IMMUNOLOGY RESEARCH (2014)
Risk of hypothyroidism in patients with cancer treated with sunitinib: A systematic review and meta-analysis
Tomohiro Funakoshi et al.
ACTA ONCOLOGICA (2013)
Hepatotoxicity of Tyrosine Kinase Inhibitors: Clinical and Regulatory Perspectives
Rashmi R. Shah et al.
DRUG SAFETY (2013)
A randomised, double-blind phase III study of pazopanib in patients with advanced and/or metastatic renal cell carcinoma: Final overall survival results and safety update
Cora N. Sternberg et al.
EUROPEAN JOURNAL OF CANCER (2013)
Cabozantinib in Progressive Medullary Thyroid Cancer
Rossella Elisei et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial
Axel Grothey et al.
LANCET (2013)
Tyrosine Kinase Inhibitor-Induced Thyroid Disorders: A Review and Hypothesis
Noriko Makita et al.
THYROID (2013)
Ipilimumab-induced autoimmune adrenalitis
Le Min et al.
LANCET DIABETES & ENDOCRINOLOGY (2013)
Could thyroid dysfunction influence outcome in sunitinib-treated metastatic renal cell carcinoma?
R. Sabatier et al.
ANNALS OF ONCOLOGY (2012)
Tyrosine Kinase Inhibitors Noncompetitively Inhibit MCT8-Mediated Iodothyronine Transport
Doreen Braun et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2012)
Vandetanib in Patients With Locally Advanced or Metastatic Medullary Thyroid Cancer: A Randomized, Double-Blind Phase III Trial
Samuel A. Wells et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial
Winette T. A. van der Graaf et al.
LANCET (2012)
Differentiated Thyroid Carcinoma After 131I-MIBG Treatment for Neuroblastoma During Childhood: Description of the First Two Cases
Hanneke M. van Santen et al.
THYROID (2012)
The impact of sunitinib-induced hypothyroidism on progression-free survival of metastatic renal cancer patients: A prospective single-center study
Valentina Baldazzi et al.
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS (2012)
The blockade of immune checkpoints in cancer immunotherapy
Drew M. Pardoll
NATURE REVIEWS CANCER (2012)
Hypothyroidism in Patients With Renal Cell Carcinoma Blessing or Curse?
Manuela Schmidinger et al.
CANCER (2011)
Sunitinib-Induced Hypothyroidism Is due to Induction of Type 3 Deiodinase Activity and Thyroidal Capillary Regression
Mariette H. W. Kappers et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2011)
Comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity
Theonie Anastassiadis et al.
NATURE BIOTECHNOLOGY (2011)
Sunitinib Malate for the Treatment of Pancreatic Neuroendocrine Tumors.
Eric Raymond et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Thyroid and Hepatic Function After High-Dose 131I-Metaiodobenzylguanidine (131I-MIBG) Therapy for Neuroblastoma
Alekist Quach et al.
PEDIATRIC BLOOD & CANCER (2011)
Hypothyroidism correlates with a better prognosis in metastatic renal cancer patients treated with sorafenib or sunitinib
L. M. Riesenbeck et al.
WORLD JOURNAL OF UROLOGY (2011)
Sorafenib-Induced Hypothyroidism Is Associated with Increased Type 3 Deiodination
Randa M. Abdulrahman et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2010)
Thyrotoxicosis during sunitinib treatment for renal cell carcinoma
Mathis Grossmann et al.
CLINICAL ENDOCRINOLOGY (2008)
EANM procedure guidelines for 131I-meta-iodobenzylguanidine (131I-mIBG) therapy
Francesco Giammarile et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2008)
Sunitinib (sutent)-induced thyrotoxicosis due to destructive thyroiditis: A case report
Jason E. Faris et al.
THYROID (2007)
Sunitinib versus interferon alfa in metastatic renal-cell carcinoma
Robert J. Motzer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Hypothyroidism after sunitinib treatment for patients with gastrointestinal stromal tumors
Jayesh Desai et al.
ANNALS OF INTERNAL MEDICINE (2006)
Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial
George D. Demetri et al.
LANCET (2006)
Imatinib induces hypothyroidism in patients receiving levothyroxinc
JWB de Groot et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2005)
Improved radiation protection of the thyroid gland with thyroxine, methimazole, and potassium iodide during diagnostic and therapeutic use of radiolabeled metaiodobenzylguanidine in children with neuroblastoma
HM van Santen et al.
CANCER (2003)
Thyroid peroxidase and thyroglobulin autoantibodies in a large survey of populations with mild and moderate iodine deficiency
IB Pedersen et al.
CLINICAL ENDOCRINOLOGY (2003)
High incidence of thyroid dysfunction despite prophylaxis with potassium iodide during 131I-meta-iodobenzylguanidine treatment in children with neuroblastoma
HM van Santen et al.
CANCER (2002)
Share Paper
